Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase

Blood

Volumn 117, Issue 17, 2011, Pages 4658-4666

  Kazerounian, Shideh ^a   Duquette, Mark ^a   Reyes, Millys A ^a   Lawler, James T ^a   Song, Keli ^a   Perruzzi, Carole ^a   Primo, Luca ^b   Khosravi Far, Roya ^a   Bussolino, Federico ^b   Rabinovitz, Isaac ^c   Lawler, Jack ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; PROTEIN KINASE SYK; THROMBOSPONDIN 1; TYROSINE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 79955965433     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-305284     Document Type: Article

References (48)

1. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785-791. (Pubitemid 32880285)
2. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989; 58(1):95-101. (Pubitemid 19180082)
3. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274(27):19055-19062.
4. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 1996;87(5):2020-2028. (Pubitemid 26068918)
5. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000;19(7): 597-614.
6. DawsonDW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138(3):707-717. (Pubitemid 27349849)
7. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6(1): 41-48. (Pubitemid 30048524)
8. Primo L, Ferrandi C, Roca C, et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 2005;19(12):1713-1715. (Pubitemid 41429539)
9. Jimenez B, Volpert OV, Reiher F, et al. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene. 2001;20(26):3443-3448. (Pubitemid 32588993)
10. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res. 2000;37(3):209-218. (Pubitemid 30350890)
11. Sun J, Hopkins BD, Tsujikawa K, et al. Thrombospondin- 1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol. 2009; 296(5):H1344-H1351.
12. Dorahy DJ, Berndt MC, Shafren DR, Burns GF. CD36 is spatially associated with glycoprotein IIb-IIIa (alpha IIb beta 3) on the surface of resting platelets. Biochem Biophys Res Commun. 1996; 218(2):575-581. (Pubitemid 26040787)
13. Miao WM, Vasile E, Lane WS, Lawler J. CD36 associates with CD9 and integrins on human blood platelets. Blood. 2001;97(6):1689-1696. (Pubitemid 32217235)
14. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem. 2001;276(11):7974-7984.
15. Bull HA, Brickell PM, Dowd PM. Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett. 1994; 351(1):41-44.
16. Thorne RF, Law EG, Elith CA, Ralston KJ, Bates RC, Burns GF. The association between CD36 and Lyn protein tyrosine kinase is mediated by lipid. Biochem Biophys Res Commun. 2006;351(1):51-56. (Pubitemid 44635405)
17. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005; 168(4):643-653. (Pubitemid 40271029)
18. Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF. The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem. 2000;275(45):35264-35275.
19. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood. 1992; 80(5):1105-1115.
20. Blonder J, Yu LR, Radeva G, et al. Combined chemical and enzymatic stable isotope labeling for quantitative profiling of detergent-insoluble membrane proteins isolated using Triton X-100 and Brij-96. J Proteome Res. 2006;5(2):349-360. (Pubitemid 43222303)
21. Peskan T, Westermann M, Oelmuller R. Identification of low-density Triton X-100-insoluble plasma membrane microdomains in higher plants. Eur J Biochem. 2000;267(24):6989-6995. (Pubitemid 32009440)
22. Olsson AK, DimbergA, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
23. Miranti CK, Leng L, Maschberger P, Brugge JS, Shattil SJ. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Curr Biol. 1998;8(24):1289-1299. (Pubitemid 29006704)
24. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6(10): 801-811. (Pubitemid 41726118)
25. Stipp CS, Kolesnikova TV, Hemler ME. EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J Biol Chem. 2001; 276(44):40545-40554.
26. Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009;23(10):3368-3376.
27. Santos SC, Miguel C, Domingues I, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313(8):1561-1574. (Pubitemid 46589434)
28. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol. 2006;174(4):593-604. (Pubitemid 44231870)
29. Zeng Y, Tao N, Chung KN, Heuser JE, Lublin DM. Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1. J Biol Chem. 2003;278(46):45931-45936. (Pubitemid 37432739)
30. Inatome R, Yanagi S, Takano T, Yamamura H. A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2001;286(1):195-199. (Pubitemid 32917669)
31. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
32. Lupher ML Jr, Rao N, Lill NL, et al. Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem. 1998;273(52):35273-35281. (Pubitemid 29028235)
33. Moon KD, Post CB, Durden DL, et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005;280(2):1543-1551.
34. Meyer RD, Sacks DB, Rahimi N. IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis. PLoS ONE. 2008;3(12):e3848.
35. Dougher M, Terman BI. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene. 1999;18(8):1619-1627. (Pubitemid 29108062)
36. Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun. 1994;205(1):728-738.
37. Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5- ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003;306(3):1174-1181. (Pubitemid 37025329)
38. Holmqvist K, Cross MJ, Rolny C, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267- 22275. (Pubitemid 38679423)
39. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10): 2003-2012. (Pubitemid 47354167)
40. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 2005;102(4): 1076-1081. (Pubitemid 40170728)
41. Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A. 1991;88(17):7844-7848. (Pubitemid 21915251)
42. Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME. A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem. 1997;272(5):2595-2598. (Pubitemid 27053987)
43. Vlahakis NE, Young BA, Atakilit A, et al. Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem. 2007; 282(20):15187-15196. (Pubitemid 47093385)
44. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18(4):882-892. (Pubitemid 29082268)
45. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285(50): 38923-38932.
46. Hughes CE, Pollitt AY, Mori J, et al. CLEC-2 activates Syk through dimerization. Blood. 2010; 115(14):2947-2955.
47. Spalton JC, Mori J, PollittAY, Hughes CE, Eble JA, Watson SP. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost. 2009;7(7):1192-1199.
48. Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell. 2002; 10(5):1057-1069. (Pubitemid 36001972)